Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors

Off-label marketing and kickbacks may no longer be the top targets of government healthcare fraud investigations as more companies are being hit with subpoenas for pricing information.

United States Department of Justice headquarter building in Washington D.C.

Drug makers have been unable to shake free of government investigations of their marketing and sales practices. But the focus of the probes has shifted in the last few years and one word now routinely pops up – pricing.

That has been the hot button issue roiling industry the past year as several companies have been excoriated by Congress...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet